Oladapo Olumoroti Yeku, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
CA-125 Antigen | 4 | 2024 | 279 | 1.250 |
Why?
|
Ovarian Neoplasms | 11 | 2024 | 4878 | 1.180 |
Why?
|
Immunotherapy, Adoptive | 5 | 2023 | 1454 | 1.050 |
Why?
|
Antigen-Antibody Reactions | 1 | 2024 | 346 | 0.910 |
Why?
|
Membrane Proteins | 4 | 2024 | 7850 | 0.810 |
Why?
|
Endometrial Neoplasms | 4 | 2024 | 1357 | 0.740 |
Why?
|
T-Lymphocytes | 6 | 2023 | 10181 | 0.690 |
Why?
|
Receptors, Antigen, T-Cell | 3 | 2023 | 2536 | 0.690 |
Why?
|
Acidosis, Lactic | 1 | 2021 | 145 | 0.680 |
Why?
|
Genetic Counseling | 1 | 2023 | 624 | 0.670 |
Why?
|
DNA Mismatch Repair | 2 | 2022 | 429 | 0.670 |
Why?
|
Antibodies, Bispecific | 1 | 2021 | 191 | 0.620 |
Why?
|
Vulvar Neoplasms | 1 | 2020 | 263 | 0.600 |
Why?
|
DNA, Complementary | 2 | 2011 | 1991 | 0.540 |
Why?
|
Neuroblastoma | 1 | 2023 | 1252 | 0.480 |
Why?
|
Radium | 1 | 2015 | 72 | 0.470 |
Why?
|
Brachytherapy | 1 | 2022 | 1238 | 0.460 |
Why?
|
Metformin | 1 | 2021 | 912 | 0.440 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2021 | 1529 | 0.420 |
Why?
|
Tumor Microenvironment | 6 | 2020 | 3844 | 0.360 |
Why?
|
Cell Line, Tumor | 8 | 2024 | 16939 | 0.320 |
Why?
|
Acute Kidney Injury | 1 | 2021 | 1941 | 0.320 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2011 | 330 | 0.310 |
Why?
|
Ascites | 3 | 2020 | 338 | 0.310 |
Why?
|
Hypoglycemic Agents | 1 | 2021 | 3150 | 0.310 |
Why?
|
Healthcare Disparities | 1 | 2023 | 3388 | 0.300 |
Why?
|
Immunotherapy | 3 | 2020 | 4642 | 0.290 |
Why?
|
Inflammation Mediators | 1 | 2016 | 1881 | 0.280 |
Why?
|
Blood Proteins | 2 | 2024 | 1173 | 0.280 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2020 | 4024 | 0.240 |
Why?
|
Alternative Splicing | 1 | 2009 | 1091 | 0.220 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 11712 | 0.220 |
Why?
|
Colorectal Neoplasms | 1 | 2023 | 6853 | 0.220 |
Why?
|
Bone Neoplasms | 1 | 2015 | 2532 | 0.210 |
Why?
|
Antineoplastic Agents | 4 | 2023 | 13630 | 0.210 |
Why?
|
bcl-X Protein | 1 | 2024 | 413 | 0.200 |
Why?
|
Indazoles | 1 | 2024 | 302 | 0.200 |
Why?
|
Galectin 3 | 1 | 2024 | 240 | 0.200 |
Why?
|
Galectins | 2 | 2024 | 282 | 0.200 |
Why?
|
Xenograft Model Antitumor Assays | 5 | 2021 | 3584 | 0.200 |
Why?
|
Pyrimidinones | 1 | 2024 | 384 | 0.190 |
Why?
|
Oncogene Proteins, Viral | 1 | 2023 | 341 | 0.190 |
Why?
|
Cytokines | 1 | 2016 | 7343 | 0.190 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 2021 | 303 | 0.170 |
Why?
|
Macrophages, Peritoneal | 1 | 2020 | 237 | 0.170 |
Why?
|
Drug Synergism | 2 | 2021 | 1754 | 0.170 |
Why?
|
Fluorescence | 1 | 2022 | 751 | 0.170 |
Why?
|
Cystadenocarcinoma, Serous | 1 | 2024 | 479 | 0.170 |
Why?
|
Phospholipase D | 2 | 2010 | 67 | 0.160 |
Why?
|
Pyridones | 1 | 2024 | 792 | 0.160 |
Why?
|
Aniline Compounds | 1 | 2024 | 1069 | 0.160 |
Why?
|
Neoplasms | 4 | 2024 | 22072 | 0.150 |
Why?
|
Genital Neoplasms, Female | 1 | 2023 | 533 | 0.150 |
Why?
|
Nausea | 1 | 2021 | 678 | 0.150 |
Why?
|
Fluorouracil | 1 | 2023 | 1631 | 0.150 |
Why?
|
Humans | 30 | 2024 | 760621 | 0.150 |
Why?
|
Single-Chain Antibodies | 1 | 2018 | 111 | 0.150 |
Why?
|
Tumor Escape | 1 | 2020 | 370 | 0.150 |
Why?
|
Ligands | 3 | 2022 | 3276 | 0.140 |
Why?
|
RNA, Messenger | 2 | 2011 | 12766 | 0.140 |
Why?
|
Losartan | 1 | 2019 | 265 | 0.140 |
Why?
|
Female | 19 | 2024 | 391270 | 0.140 |
Why?
|
Antibodies, Monoclonal | 3 | 2023 | 9185 | 0.140 |
Why?
|
Vagina | 1 | 2022 | 837 | 0.130 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 1728 | 0.130 |
Why?
|
Piperidines | 1 | 2024 | 1650 | 0.130 |
Why?
|
Creatinine | 1 | 2021 | 1903 | 0.130 |
Why?
|
Uterine Neoplasms | 1 | 2024 | 1439 | 0.120 |
Why?
|
Interleukin-12 | 1 | 2017 | 584 | 0.120 |
Why?
|
DNA Repair | 1 | 2024 | 2039 | 0.120 |
Why?
|
Cisplatin | 1 | 2020 | 1644 | 0.120 |
Why?
|
Diarrhea | 1 | 2021 | 1319 | 0.120 |
Why?
|
Sulfonamides | 1 | 2024 | 1977 | 0.120 |
Why?
|
Peritoneal Neoplasms | 1 | 2020 | 707 | 0.120 |
Why?
|
Transforming Growth Factor alpha | 1 | 2014 | 135 | 0.110 |
Why?
|
Radioisotopes | 1 | 2015 | 495 | 0.110 |
Why?
|
Tissue Inhibitor of Metalloproteinase-1 | 1 | 2014 | 151 | 0.110 |
Why?
|
Prostatic Neoplasms | 1 | 2016 | 11345 | 0.110 |
Why?
|
Stromal Cells | 1 | 2019 | 1326 | 0.110 |
Why?
|
Immune System | 1 | 2018 | 798 | 0.100 |
Why?
|
Receptors, Tumor Necrosis Factor, Type II | 1 | 2014 | 346 | 0.100 |
Why?
|
Mice | 10 | 2024 | 81208 | 0.090 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2020 | 1889 | 0.090 |
Why?
|
Papillomavirus Infections | 1 | 2023 | 1607 | 0.090 |
Why?
|
Referral and Consultation | 1 | 2023 | 3598 | 0.090 |
Why?
|
Lymph Nodes | 1 | 2022 | 3486 | 0.090 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2021 | 3484 | 0.090 |
Why?
|
Animals | 12 | 2024 | 167963 | 0.080 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2022 | 9276 | 0.080 |
Why?
|
Domperidone | 1 | 2008 | 24 | 0.080 |
Why?
|
Disease Models, Animal | 4 | 2021 | 18137 | 0.080 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2024 | 5253 | 0.080 |
Why?
|
Phosphotransferases (Alcohol Group Acceptor) | 1 | 2011 | 436 | 0.080 |
Why?
|
DNA-Binding Proteins | 2 | 2023 | 9585 | 0.070 |
Why?
|
Oligonucleotides | 1 | 2011 | 588 | 0.070 |
Why?
|
DNA Primers | 1 | 2011 | 2819 | 0.070 |
Why?
|
Diagnosis, Differential | 1 | 2021 | 12965 | 0.060 |
Why?
|
Chemotaxis | 1 | 2008 | 598 | 0.060 |
Why?
|
Aged | 6 | 2024 | 169152 | 0.060 |
Why?
|
Cell Movement | 2 | 2024 | 5206 | 0.060 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2023 | 2864 | 0.050 |
Why?
|
Rad51 Recombinase | 1 | 2024 | 188 | 0.050 |
Why?
|
Treatment Outcome | 4 | 2024 | 65017 | 0.050 |
Why?
|
Papillomavirus E7 Proteins | 1 | 2023 | 111 | 0.050 |
Why?
|
Ribose | 1 | 2022 | 63 | 0.050 |
Why?
|
HLA-A Antigens | 1 | 2023 | 225 | 0.050 |
Why?
|
Diphosphates | 1 | 2022 | 84 | 0.050 |
Why?
|
Mutation | 2 | 2024 | 29932 | 0.050 |
Why?
|
Mice, Inbred C57BL | 2 | 2018 | 22023 | 0.050 |
Why?
|
C-Reactive Protein | 1 | 2014 | 3839 | 0.050 |
Why?
|
Autophagy | 1 | 2010 | 1337 | 0.050 |
Why?
|
Cells, Cultured | 1 | 2017 | 18957 | 0.050 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 4573 | 0.050 |
Why?
|
Apoptosis | 1 | 2017 | 9501 | 0.050 |
Why?
|
Coronary Artery Disease | 1 | 2021 | 6659 | 0.050 |
Why?
|
Human papillomavirus 16 | 1 | 2023 | 265 | 0.050 |
Why?
|
GTP Phosphohydrolases | 1 | 2024 | 518 | 0.050 |
Why?
|
Survival Rate | 1 | 2015 | 12808 | 0.050 |
Why?
|
Carboplatin | 1 | 2023 | 788 | 0.040 |
Why?
|
Phthalazines | 1 | 2022 | 383 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2016 | 10344 | 0.040 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2024 | 607 | 0.040 |
Why?
|
Paracrine Communication | 1 | 2020 | 277 | 0.040 |
Why?
|
Prognosis | 4 | 2024 | 29658 | 0.040 |
Why?
|
Spheroids, Cellular | 1 | 2020 | 329 | 0.040 |
Why?
|
Glucose | 1 | 2011 | 4351 | 0.040 |
Why?
|
Phosphorylation | 1 | 2009 | 8313 | 0.040 |
Why?
|
Cricetulus | 2 | 2010 | 815 | 0.040 |
Why?
|
Autocrine Communication | 1 | 2018 | 169 | 0.040 |
Why?
|
BRCA1 Protein | 1 | 2024 | 1147 | 0.040 |
Why?
|
Microscopy, Electron | 2 | 2011 | 2558 | 0.030 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2021 | 12293 | 0.030 |
Why?
|
Heart Failure | 1 | 2021 | 11847 | 0.030 |
Why?
|
Interleukin-18 | 1 | 2018 | 251 | 0.030 |
Why?
|
CHO Cells | 2 | 2010 | 1389 | 0.030 |
Why?
|
Gene Knockdown Techniques | 1 | 2021 | 1617 | 0.030 |
Why?
|
Insulin | 1 | 2011 | 6597 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2023 | 1827 | 0.030 |
Why?
|
Middle Aged | 4 | 2024 | 220352 | 0.030 |
Why?
|
Cricetinae | 2 | 2010 | 2427 | 0.030 |
Why?
|
Cell Proliferation | 2 | 2024 | 10446 | 0.030 |
Why?
|
Mice, Knockout | 3 | 2020 | 14372 | 0.030 |
Why?
|
Melanoma | 1 | 2014 | 5697 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2022 | 21025 | 0.030 |
Why?
|
Mice, Nude | 1 | 2021 | 3607 | 0.030 |
Why?
|
Receptors, Estrogen | 1 | 2022 | 2210 | 0.030 |
Why?
|
Indoles | 1 | 2022 | 1829 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2020 | 8515 | 0.030 |
Why?
|
Quality of Life | 1 | 2015 | 13308 | 0.030 |
Why?
|
Mice, SCID | 1 | 2018 | 2627 | 0.030 |
Why?
|
Retrospective Studies | 1 | 2022 | 80372 | 0.030 |
Why?
|
Receptor, erbB-2 | 1 | 2022 | 2554 | 0.020 |
Why?
|
Male | 4 | 2024 | 359744 | 0.020 |
Why?
|
Stress, Physiological | 1 | 2019 | 1398 | 0.020 |
Why?
|
Extracellular Matrix | 1 | 2019 | 1726 | 0.020 |
Why?
|
Collagen | 1 | 2019 | 2636 | 0.020 |
Why?
|
Class III Phosphatidylinositol 3-Kinases | 1 | 2010 | 17 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2023 | 3758 | 0.020 |
Why?
|
DNA | 1 | 2024 | 7233 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2021 | 2803 | 0.020 |
Why?
|
Aged, 80 and over | 2 | 2024 | 58995 | 0.020 |
Why?
|
Obesity | 1 | 2011 | 12922 | 0.020 |
Why?
|
Neovascularization, Pathologic | 1 | 2019 | 2640 | 0.020 |
Why?
|
HL-60 Cells | 1 | 2008 | 363 | 0.020 |
Why?
|
Cell Survival | 1 | 2018 | 5797 | 0.020 |
Why?
|
Androstadienes | 1 | 2010 | 348 | 0.020 |
Why?
|
Glucose Tolerance Test | 1 | 2011 | 1175 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2024 | 5643 | 0.020 |
Why?
|
NIH 3T3 Cells | 1 | 2008 | 670 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2019 | 3562 | 0.020 |
Why?
|
Cytoskeleton | 1 | 2011 | 1167 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2010 | 2471 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2018 | 4742 | 0.010 |
Why?
|
Islets of Langerhans | 1 | 2011 | 1345 | 0.010 |
Why?
|
Microtubule-Associated Proteins | 1 | 2010 | 1077 | 0.010 |
Why?
|
Adult | 3 | 2024 | 219994 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2019 | 11152 | 0.010 |
Why?
|
Microscopy, Confocal | 1 | 2010 | 1972 | 0.010 |
Why?
|
Transcription Factors | 1 | 2023 | 12103 | 0.010 |
Why?
|
Disease Progression | 1 | 2020 | 13502 | 0.010 |
Why?
|
HeLa Cells | 1 | 2010 | 3105 | 0.010 |
Why?
|
Actins | 1 | 2011 | 2049 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2014 | 6828 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2014 | 6544 | 0.010 |
Why?
|
MicroRNAs | 1 | 2019 | 3790 | 0.010 |
Why?
|
Blotting, Western | 1 | 2010 | 5039 | 0.010 |
Why?
|
Signal Transduction | 2 | 2018 | 23376 | 0.010 |
Why?
|
Cohort Studies | 1 | 2024 | 41335 | 0.010 |
Why?
|
Homeostasis | 1 | 2011 | 3306 | 0.010 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2010 | 2895 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2014 | 12531 | 0.010 |
Why?
|
tau Proteins | 1 | 2010 | 2085 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2008 | 3726 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2011 | 11071 | 0.010 |
Why?
|
Skin Neoplasms | 1 | 2014 | 5799 | 0.010 |
Why?
|
Diet | 1 | 2011 | 8010 | 0.010 |
Why?
|
Risk Factors | 1 | 2014 | 74359 | 0.000 |
Why?
|